Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials

IMPORTANCE: For men with metastatic castration-resistant prostate cancer (mCRPC) whose condition is responding to enzalutamide, new unconfirmed bone lesions detected at posttreatment scinitigraphy may reflect an osteoblastic reaction that represents healing, known as pseudoprogression, which can lea...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Main Authors: Armstrong, Andrew J., Al-Adhami, Mohammed, Lin, Ping, Parli, Teresa, Sugg, Jennifer, Steinberg, Joyce, Tombal, Bertrand, Sternberg, Cora N., de Bono, Johann, Scher, Howard I., Beer, Tomasz M.
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2019
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990871/
https://ncbi.nlm.nih.gov/pubmed/31830211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.4636
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares